Publisher
Computers, Materials and Continua (Tech Science Press)
Reference26 articles.
1. Armitage J, Vose J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26: 4124–4130
2. Coiffier B, Pro B, Prince HM, et al (2010) Final results from a pivotal, multicenter, International, Open-Label, Phase 2 Study of Romidepsin in Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) following prior systemic therapy. Blood (ASH Annual Meeting Abstracts) 116: Abstract 114
3. Czuczman MS, Porcu P, Johnson J, et al. (2007) Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma 48: 97–103
4. Damaj G, Gressin R, Bouhabdallah K, et al (2011) Preliminary results from an open-label, multicenter, phase II study of bendamustine in relapsed or refractory T-cell lymphoma from the French GOELAMS Group: the Bently trial. Ann Oncol 22: Abstract 126
5. d’Amore F, Radford J, Relander T, et al. (2010) Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T-cell lymphoma. Br J Haematol 150: 565–573